Pathologic Responses Result From Neoadjuvant SBRT Plus Cemiplimab in Resectable HCC

Press/Media

Period	11 Jan 2024

Media coverage

Title	Pathologic Responses Result From Neoadjuvant SBRT Plus Cemiplimab in Resectable HCC
Media name/outlet	Oncology Nursing News
Country/Territory	United States
Date	11/01/24
URL	https://www.oncnursingnews.com/view/pathologic-responses-result-from-neoadjuvant-sbrt-plus-cemiplimab-in-resectable-hcc
Persons	Thomas Marron